Valley Fever Solutions

Bringing New Hope to an Orphan Disease

Valley Fever Solutions
Ask your doctor to test you for Valley Fever

A first-in-class compound, New Mechanism of Action

News - VFS at upcoming 7th International Cocci Study Group

We are excited to join once again the Coccidioidomycosis Study Group meeting, this year at Stanford Medical School, August 10-13, 2017, celebrating their 61st continuous year of meetings. This decennial international meeting convenes the leading experts in coccidioidomycosis from around the world. The proceedings from previous decennial meetings are published.
   Cocci Study Group;    Stanford Medical School Cocci Meeting
Our Dr. Galgiani has been a leader in the group since the 1980s. Our David Larwood has been active since 2006. Two founders remain active in the group. Another founder, Hans Einstein, who left us in 2012, will be represented by several of his children. David's father joined the group in its third year, 1959. David's mother joined in 1997, in connection with her leading the Valley Fever Americas Foundation, raising millions for vaccine development.

Nikkomycin Z (NikZ) is first in a new class of antifungal
  • Novel mechanism of action, expected to raise the standard of care
  • Selective to fungal cells - thus far no safety concerns in mammals
  • May enhance other anti-fungal treatments in combination with other drugs
  • Scaled up trial material in process, Phase IIa trials in sick humans Summer 2017

Valley Fever Solutions, Inc. (VFS, an Arizona corporation), is developing Nikkomycin Z (NikZ) as a dramatically superior potential cure for Valley Fever. VF is a painful and debilitating orphan disease causing annually over 2,000 serious cases, 9K hospitalizations, and 150 deaths. About 60,000 people are sickened each year, suffering for months. Victims with more serious cases suffer for years. Each year, another 1,000 patients have serious disease - with no therapeutic options, as the current drugs do not work for them.

Collectively, the market for antifungals across a spectrum of similar disease organisms approaches $1B. Broadly, worldwide antifungal sales exceed $6B. NikZ for Valley Fever, our first indication, has Orphan Product designation. In 2014 we added GAIN Act QIDP designation. These provide for 7 and 5 years sequential market exclusivity after marketing approval. We expect to reach peak sales of $130M for Valley Fever fairly quickly with our many advantages over standard-of-care drugs. We expect therapeutic benefit in other indications in immunosuppressed patients, expecting a 2-3x market multiplier.

Our Phase I results were very promising. We are pursuing patents related to the new manufacturing process for NikZ. VFS is seeking a tranched A round or a partnership to reach proof of concept in late 2017. We could start a pivotal trial in late 2017 with support now.

We anticipate showing human efficacy working with an existing trial at the NIH. We are seeking $2M to conduct a small proof of concept trial much sooner in a small population of more typical subjects, our "sweet spot" trial. We are making progress under an NIH grant to conduct a clinical trial in patients with new infection, a trial we hope to begin in late 2017. An NIH contract delivered some GMP product by an older process.

We are scaling up our pilot scale process to make a large batch of new trial material (API and drug product) in May 2017. We will begin Phase IIa patient enrollment shortly after having trial material, anticipating results 3-6 months later, and early results within the first 2 months (endpoint confirmation). With investor support, the sweet spot proof of concept trial could give results as soon as Fall 2017. Such private funding would accelerate the NIH proof of concept path by a year or more. We expect to be a good candidate for an additional $2M FDA orphan product trial grant in 2018.

Valley Fever Solutions

1830 E. Broadway, #124-182
Tucson, AZ 85719
Tel: 650-454-4126
‚Äč Mail:

Resources... Next Page ⟩
  • Cocci Study Group, August 10-13, 2017
  • Seventh International Cocci conference

  • BIO, June 19-22, 2017, San Diego
  • Premiere International BIO conference

  • Cavendish, May 7-9, 2017, Washington DC
  • Investor Conference

  • WODC April 20-21, 2017, Washington, D.C.
  • World Orphan Drug Conference

    Temple at Nikko, Japan where the organism that produces Nikkomycin-Z was discovered

    Temple at Nikko, Japan